NCT05222620 2026-04-13
SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
Mayo Clinic
Phase 2 Recruiting
Clinical Trials
14 trialsNCT02971501 2026-03-17
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06667726 2026-03-16
An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors
Mayo Clinic
Phase 2 Not yet recruiting
NCT04044937 2026-03-11
UC-GlioFET
University of California, San Francisco
Phase 2 Completed
NCT03270059 2026-02-27
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
OHSU Knight Cancer Institute
Phase 2 Recruiting
NCT06132685 2026-02-10
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
Emory University
Phase 2 Recruiting
NCT05840770 2025-05-26
Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT03649880 2025-03-25
Feasibility of FMISO in Brain Tumors
OHSU Knight Cancer Institute
Phase 2 Recruiting
NCT02073968 2024-01-25
PAINT
Albert Einstein College of Medicine
Phase 2 Completed
NCT03234309 2021-11-10
Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT02120287 2019-05-07
Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme
University of Pittsburgh
Phase 2 Completed
NCT02796729 2019-01-28
CEST- Glucose Enhanced MRI for Metastatic Brain Tumours
British Columbia Cancer Agency
Phase 2 Terminated
NCT00492089 2014-05-09
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00805636 2010-05-12
Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.
Aposense Ltd.
Phase 2 Unknown